Helix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Helix and buy or sell other stocks, ETFs, and their options commission-free!

About HLXA

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. 

CEO
Jorge Santos da Silva, PhD
CEOJorge Santos da Silva, PhD
Employees
130
Employees130
Headquarters
Zug, Zug
HeadquartersZug, Zug
Founded
2021
Founded2021
Employees
130
Employees130

HLXA Key Statistics

Market cap
955.78M
Market cap955.78M
Price-Earnings ratio
-4.91
Price-Earnings ratio-4.91
Dividend yield
Dividend yield
Average volume
987.14K
Average volume987.14K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$62.75
52 Week high$62.75
52 Week low
$5.95
52 Week low$5.95

Stock Snapshot

With a market cap of 955.78M, Helix(HLXA) trades at $13.25. The stock has a price-to-earnings ratio of -4.91.

During the trading day, Helix(HLXA) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 987.14K.

The stock's 52-week range extends from a low of $5.95 to a high of $62.75.

The stock's 52-week range extends from a low of $5.95 to a high of $62.75.

People also own

Based on the portfolios of people who own HLXA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.